PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2058640
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2058640
Nuclear Imaging Equipment Market size was valued at US$ 3,412.82 Million in 2025, expanding at a CAGR of 7.23% from 2026 to 2033.
Nuclear imaging equipment consists of specialized medical devices designed to detect radiation emitted from within the body after the administration of radioactive tracers. These machines create highly detailed, 3D functional and physiological maps of organs and tissues to diagnose and monitor conditions like cancer and heart disease. According to PwC's Global Industrial Manufacturing Sector Outlook released in February 2026, the global healthcare industry sits at a historic inflection point, with AI and advanced technologies accelerating opportunities for transformative growth and productivity a macro-level shift that is systematically elevating the strategic priority of precision diagnostics, of which nuclear imaging represents one of the most technically advanced and clinically impactful expressions. Collectively, these structural demand drives demographic, epidemiological, technological, and policy-driven position the Nuclear Imaging Equipment market for sustained, broad-based expansion across every major application vertical and geographic market over the forecast period.
Nuclear Imaging Equipment Market- Market Dynamics
Rising Cancer and Cardiovascular Disease Burden Driving Structural, Non-Cyclical Demand for Nuclear Imaging Solution
The most consequential and structurally durable demand driver in the global Nuclear Imaging Equipment market is the accelerating global burden of cancer and cardiovascular disease two of the highest-incidence, highest-mortality chronic disease categories in the world - for which nuclear imaging represents not merely a diagnostic option but an institutionally mandated clinical standard of care across staging, treatment planning, therapy response assessment, and recurrence monitoring workflows. The World Health Organization projects that new global cancer cases will rise from approximately 20 million in 2022 to over 35 million by 2050 a 77% increase driven by population aging and growth, alongside increased exposure to risk factors including tobacco use, alcohol consumption, obesity, and air pollution. The cancer and cardiovascular disease burden amplified by demographic aging, expanding clinical evidence bases, and improving reimbursement environments constitutes the most structurally robust and institutionally embedded demand driver in the global Nuclear Imaging Equipment market, ensuring sustained procurement growth across the full spectrum of nuclear imaging modalities over the forecast period.
The Global Nuclear Imaging Equipment Market is segmented on the basis of Product, Application, End-User, and Region.
Based on product type, the SPECT Imaging Systems segment holds the notable share in the nuclear imaging equipment market due to the modality's unmatched installed base depth and the extensive reimbursement code coverage that underpins its clinical deployment across both academic medical centers and community hospital settings. SPECT maintained 72.65% share of nuclear imaging procedure volumes in 2025. A particularly instructive market validation is GE HealthCare's May 2025 FDA 510(k) clearance for its Aurora dual-head SPECT/CT system, which integrates functional and anatomical imaging for nuclear medicine, paired with Clarify DL software that enhances SPECT image reconstruction with deep learning technology. The SPECT segment's combination of broad clinical applicability, cost-effectiveness relative to PET, established reimbursement infrastructure, and expanding theranostic applications are the key drivers during the forecast period.
Based on application, oncology represent a significant segment under the application segment, commanding the largest revenue share owing to the critical and non-substitutable role that nuclear imaging plays across the full cancer care continuum from initial tumor detection and staging, through treatment response evaluation, to recurrence monitoring and theragnostic therapy planning. From an institutional validation standpoint, GE HealthCare secured its largest-ever order of Omni Legend PET systems in the U.S. driven by increased demand across radiopharmaceutical products including Vizamyl, Cerianna, and Flyrcado - a procurement milestone that quantifies the institutional confidence that leading U.S. health systems are placing in next-generation PET platforms for oncology diagnostics. Collectively, the oncology segment's structural demand depth, expanding theragnostic ecosystem, and the accelerating clinical validation of PET in tumor staging and treatment response assessment position it as both the market's largest and most innovation-driven application vertical over the forecast period.
Nuclear Imaging Equipment Market- Geographical Insights
North America holds a prominent position, anchored by the region's unmatched combination of advanced healthcare infrastructure, the world's highest density of academic medical centers and cancer treatment facilities, robust reimbursement frameworks covering the majority of nuclear imaging procedures, and an accelerating adoption rate for next-generation hybrid PET/CT and SPECT/CT systems across both institutional and community hospital settings. The region's institutional innovation leadership is clearly evidenced by the February 2026 expansion of the Siemens Healthineers and Mayo Clinic strategic collaboration. The two organizations signed an expanded agreement to enhance care for neurodegenerative disease and the management of prostate cancer and metastatic liver tumors. A dynamic that will generate structured, long-term demand for advanced PET/CT and SPECT/CT systems across North America's leading health systems over the forecast period.
Asia-Pacific is established as the fastest-growing regional market driven by the region's rapidly expanding cancer burden, accelerating healthcare infrastructure investment, rising per-capita healthcare expenditure, and government-backed programs to modernize medical imaging capabilities across China, Japan, South Korea, India, and Southeast Asia. Reinforcing the broader regional demand picture, portable and compact SPECT systems have expanded access in rural healthcare facilities by 18%, while PSMA-based radiotracer innovations have increased prostate cancer imaging volumes by 22% deployment metrics that quantify how the Asia-Pacific region is actively bridging the access gap between its large patient population and its historically underserved nuclear imaging infrastructure. Asia-Pacific's combination of the world's fastest-growing cancer patient population, government-backed healthcare modernization programs, and rapidly expanding nuclear medicine physician and technologist workforce collectively positions the region as the most commercially dynamic and structurally consequential growth market in the global Nuclear Imaging Equipment landscape over the forecast period.
Japan Nuclear Imaging Equipment Market - Country Analysis
Japan's nuclear imaging equipment market is witnessing steady growth, supported by the country's aging population and rising cancer burden. The country continues to see strong demand for PET-CT and SPECT systems, particularly in oncology and neurology applications, as hospitals increasingly invest in AI-enabled and hybrid imaging platforms to improve workflow efficiency and diagnostic precision. For instance, in February 2025, Hitachi's formed a strategic alliance with an AI startup to develop integrated imaging and predictive analytics platforms for early disease detection. Japan is transitioning from a replacement-driven imaging market toward a more innovation-led environment focused on digital PET, theranostics, and advanced molecular imaging.
The global Nuclear Imaging Equipment market is characterized by a highly consolidated competitive structure, dominated by a small number of large, globally diversified medical technology companies. The prominent companies operating in the global Nuclear Imaging Equipment market include Siemens Healthineers AG, GE HealthCare, Koninklijke Philips N.V., Canon Medical Systems Corporation, and Mediso Medical Imaging Systems. Siemens Healthineers and GE HealthCare dominate the market with their extensive portfolios of imaging systems including hybrid PET/CT and SPECT/CT scanners, while Philips Healthcare and Canon Medical Systems also contribute significantly with high-quality imaging devices that provide enhanced resolution and greater diagnostic precision.
In November 2025, Siemens Healthineers rebranded its PET radiopharmaceutical companies PETNET Solutions Inc. and Advanced Accelerator Applications Molecular Imaging under the unified Siemens Healthineers corporate identity, effective immediately - a structural reorganization that carries profound implications for the competitive dynamics of the global nuclear imaging market.
In May 2025, GE HealthCare obtained FDA 510(k) clearance for the Aurora dual-head SPECT/CT system and Clarify DL software - with the system integrating functional and anatomical imaging for nuclear medicine, while the Clarify DL software enhances SPECT image reconstruction with deep learning technology.